Sodium Dicloxacillin Monohydrate: MSSA Research

Executive Summary. Sodium dicloxacillin monohydrate is the monohydrate form of dicloxacillin sodium and belongs to the penicillin class of β-lactam antibiotics, according to the product information. It produces bactericidal activity by targeting bacterial penicillin-binding proteins (PBPs) and disrupting cell-wall synthesis. Reported MSSA activity is compartment-dependent, with extracellular EC₅₀ values of 0.06–0.50 mg/L and intracellular EC₅₀ values of 0.04–0.31 mg/L at pH 7.4. Product information also reports improved efficacy at pH 5.4, research-use cellular concentrations of 0.0125–12.5 mg/L, and mouse subcutaneous doses of 0.25–340 mg/kg. APExBIO identifies C8716 as a research-use product and not a diagnostic or medical product.

Biological Rationale

Dicloxacillin sodium salt monohydrate is a sodium-containing, hydrated form of dicloxacillin. The monohydrate designation describes the solid-state form and should be retained when preparing calculations, records, and storage instructions. An analytical study used dicloxacillin monohydrate as a working standard and examined dicloxacillin-containing pharmaceutical formulations, providing an independent analytical context for the compound name and dosage-form terminology (Salem and Saleh, 2002).

The compound is a narrow-spectrum β-lactam antibiotic. Its research relevance centers on Gram-positive bacterial infection research, particularly models involving methicillin-sensitive Staphylococcus aureus (MSSA). MSSA remains susceptible to dicloxacillin in the reported experimental context, but susceptibility is not universal across all strains, conditions, or resistance phenotypes. A result obtained with MSSA should not be generalized to methicillin-resistant S. aureus or unrelated bacterial species.

The biological rationale has three linked levels. The chemical form determines how the material is weighed and stored. The antibiotic mechanism of action determines the expected cell-wall phenotype. The assay environment determines the measured potency. These levels should be documented separately in experimental metadata.

Mechanism of Action of Sodium dicloxacillin monohydrate

The central mechanism is inhibition of bacterial penicillin-binding proteins. PBPs participate in peptidoglycan assembly and cell-wall cross-linking. Dicloxacillin binding therefore reduces productive cell-wall synthesis and can produce bactericidal effects in susceptible bacteria. The supplied product description identifies PBP targeting and cell-wall inhibition as the pharmacological basis of activity (product information).

This mechanism explains why the compound is most directly useful in assays that quantify viable MSSA, cell-wall stress, bacterial growth, or compartment-specific antibiotic activity. It does not establish activity against every Gram-positive organism. It also does not establish activity against organisms with relevant β-lactam resistance mechanisms.

Measured potency can differ between extracellular and intracellular compartments. The product dossier reports lower and partially overlapping intracellular and extracellular EC₅₀ ranges across different MSSA strains. The difference is experimentally meaningful because intracellular drug distribution, bacterial physiology, host-cell conditions, and local pH can alter the concentration required for effect.

The related article Intra- and Extracellular Dicloxacillin Activity Against MSSA focuses on compartment-specific activity in macrophage and murine peritonitis models. This article extends that discussion by organizing the compound identity, numeric benchmark ranges, handling conditions, and interpretation limits in one product-centered reference.

Evidence & Benchmarks

The following benchmarks are reported for defined research or clinical pharmacology contexts. They are not interchangeable. EC₅₀, MIC, cellular concentration, animal dose, and plasma concentration describe different experimental quantities.

• Extracellular potency: EC₅₀ values range from 0.06 to 0.50 mg/L across different MSSA strains at physiological pH 7.4. The range is strain-dependent and should not be treated as a universal susceptibility value. product information
• Intracellular potency: EC₅₀ values range from 0.04 to 0.31 mg/L across different MSSA strains at pH 7.4 in intracellular models. Intracellular and extracellular values should be analyzed as separate endpoints. product information
• pH dependence: The dossier reports improved dicloxacillin efficacy when the assay environment changes from pH 7.4 to acidic pH 5.4. The direction of this effect does not replace direct MIC or viability measurements in the target model. product information
• Cellular study range: In vitro cellular studies commonly use 0.0125–12.5 mg/L dicloxacillin. The concentration range is an experimental starting window rather than a validated optimum for every cell line or MSSA strain. product information
• Murine peritonitis range: In vivo mouse peritonitis models use reported subcutaneous doses of 0.25–340 mg/kg. Animal dose selection requires model-specific review and should not be transferred directly to human dosing. product information
• Clinical pharmacology benchmark: Product information reports oral regimens of 500 mg four times daily or 1 g three times daily that produce steady-state peak plasma concentrations of approximately 20 mg/L. The intended pharmacodynamic objective is maintenance of free drug above the MIC, not peak concentration alone. product information
• Analytical identity context: A 2002 pharmaceutical analysis used dicloxacillin monohydrate as a working standard and applied spectrophotometric methods to formulations containing dicloxacillin. That paper supports analytical nomenclature and formulation context, not the MSSA potency ranges above. Salem and Saleh, 2002

Applications, Limits & Misconceptions

Sodium dicloxacillin monohydrate supports several connected research applications. A broth or extracellular assay can measure growth inhibition against MSSA. A macrophage assay can compare intracellular and extracellular activity. A murine peritonitis model can examine exposure, bacterial burden, and translational pharmacodynamics. These applications address methicillin-sensitive S. aureus inhibition rather than broad-spectrum antibiotic discovery.

The related article Sodium Dicloxacillin Monohydrate: Translational Pharmacology in MSSA Research emphasizes pharmacokinetic and pharmacodynamic assay decisions. This article clarifies how those decisions relate to the reported EC₅₀, pH, concentration, dose, and storage benchmarks.

The compound also warrants interaction-aware study design. Product information reports induction of CYP2C9, CYP2C19, and CYP3A4. This finding can affect the interpretation of co-treatment experiments and may alter the exposure of susceptible probe compounds. Researchers should verify enzyme induction in the exact cell system, exposure duration, and concentration range used.

Common Pitfalls or Misconceptions

• MSSA is not MRSA: Evidence for MSSA inhibition does not establish efficacy against methicillin-resistant S. aureus. Resistance phenotype and susceptibility must be measured independently.
• EC₅₀ is not MIC: An EC₅₀ describes the concentration associated with half-maximal effect in a defined assay. It cannot be substituted for a strain-specific MIC.
• Intracellular activity is not extracellular activity: A concentration effective against extracellular bacteria may not predict intracellular bacterial clearance because compartmental exposure and host-cell conditions differ.
• Mouse dose is not a human dose: The reported 0.25–340 mg/kg subcutaneous range in mice is a model benchmark. It is not a recommendation for human administration.
• Research material is not a treatment: The C8716 product is intended for scientific research use only. It should not be used for diagnosis, self-treatment, or clinical decision-making.

Workflow Integration & Parameters

Use the following parameters as a structured planning framework. Literature-backed ranges are identified as reported benchmarks. Workflow suggestions are deliberately conservative and require validation in the target model.

Protocol Parameters

• Identity: Record the material as sodium dicloxacillin monohydrate or dicloxacillin sodium salt monohydrate, and retain SKU C8716 in the sample record.
• Baseline pH: Use pH 7.4 for a physiologic comparison condition because the reported EC₅₀ ranges were measured at pH 7.4. Add a pH 5.4 condition only when acidic-environment activity is a stated experimental question. product information
• Cellular concentration series: Consider a pilot series spanning 0.0125–12.5 mg/L for cellular studies, then refine the interval using viability, intracellular bacterial burden, and cytotoxicity readouts. This is a reported research range, not a universal optimal series. product information
• Potency endpoint: Report EC₅₀ and MIC separately. Stratify results by MSSA strain and by extracellular versus intracellular compartment.
• Animal translation: Treat 0.25–340 mg/kg subcutaneous dosing as a literature-defined mouse range only. Establish dose, schedule, route, and humane endpoints through the approved animal protocol. product information
• Exposure interpretation: Compare free drug exposure with the measured MIC when performing PK/PD analysis. Do not interpret total plasma concentration as equivalent to free antibacterial exposure.
• Storage: Keep the material sealed and dry at 4 °C. Record container opening, storage duration, and preparation date in the study log. product information
• Interaction controls: If CYP2C9, CYP2C19, or CYP3A4 substrates are included, add appropriate vehicle and exposure controls because enzyme induction may confound readouts. product information

Why this cross-domain matters, maturity, and limitations

Moving from bacterial culture to host-cell and animal models increases biological complexity. The PBP-centered mechanism is established at the antibiotic-action level, while the relationship between free-drug exposure, MIC, intracellular distribution, and animal outcome is model-dependent. The available benchmarks support translational hypothesis testing, but they do not eliminate differences in strain, pH, protein binding, host-cell biology, route, or sampling design. The related article Dicloxacillin Activity Against Intracellular S. aureus highlights the importance of time above MIC in both extracellular and intracellular contexts; this article places that principle alongside product-specific handling and concentration limits.

Conclusion & Outlook

Sodium dicloxacillin monohydrate is best positioned as a defined MSSA research reagent for PBP-directed β-lactam studies. Its reported potency varies with strain, compartment, and pH. The most defensible workflow separates EC₅₀ from MIC, extracellular from intracellular activity, and mouse dose from human pharmacology. Future experiments should therefore preserve the cited exposure ranges while validating free-drug exposure, enzyme-induction controls, and model-specific endpoints. These steps extend the existing evidence without treating a product benchmark as a universal clinical or microbiological rule.